Volume 11, Number 6—June 2005
Research
Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs
John M. Stelling*†
, Karin Travers*, Ronald N. Jones‡§, Philip J. Turner¶, Thomas F. O'Brien*†, and Stuart B. Levy*§
, Karin Travers*, Ronald N. Jones‡§, Philip J. Turner¶, Thomas F. O'Brien*†, and Stuart B. Levy*§
Table 3
Nonsusceptibility rates of Escherichia coli by region, 2001*
| Drug | North America | Latin America | Northern Europe | Southern Europe + South Africa | Western Pacific |
|---|---|---|---|---|---|
| Ampicillin | |||||
| 20%–40% | Canada (35%) | Sweden (31%) | Italy (40%) | Japan (30%) | |
| 40%–60% | United States (44%) | Argentina, Brazil, Chile, Venezuela (54%–57%) | Belgium, France, Germany, Ireland, Switzerland, United Kingdom (46%–57%) | Greece (51%) | Australia, Singapore (50%–54%) |
| >60% | Colombia, Mexico (71%–76%) | Poland (62%–84%) | Israel, South Africa, Spain, Turkey (62%–84%) | Hong Kong, Philippines, Taiwan (64%–82%) | |
| Trimethoprim/sulfamethoxazole | |||||
| 0%–20% | Italy (19%) | Australia, Japan (11%–17%) | |||
| 20%–40% | Canada, United States (20%–23%) | Argentina, Chile (28%–39%) | Belgium, Ireland, Poland, Sweden, Switzerland, United Kingdom (20%–31%) | France, Greece, Spain (20%–31%) | |
| 40%–60% | Brazil, Colombia, Mexico, Venezuela (51%–57%) | Germany (40%) | Israel, South Africa, Turkey (42%–59%) | Hong Kong, Philippines, Singapore, Taiwan (40%–60%) | |
| Ceftazidime | |||||
| ≤5% | Canada, United States (MYS 3%, SEN 1%–2%) | Brazil, Chile (SEN 2%–4%) | Belgium, Czech Republic, Germany, Ireland, Poland, Sweden, Switzerland, United Kingdom (MYS 0%–3%, SEN 0%–3%) | Greece (SEN), France, South Africa Spain, Turkey (SEN) (MYS 4%, SEN 0%–5%) | Australia, Hong Kong, Japan, Singapore (MYS 0%, SEN 2%–3%) |
| >5% | Argentina, Colombia, Mexico, Venezuela (MYS 7%–13%, SEN 6%–11%) | Greece (MYS), Israel, Italy, Turkey (MYS) (MYS 6%–11%, SEN 6%–8%) | Philippines, Taiwan, Thailand (MYS 19%, SEN 6%) | ||
| Ciprofloxacin | |||||
| ≤10% | United States, Canada (MYS 2%–10%, SEN 7%–9%) | Argentina (MYS), Brazil (SEN) (MYS 4%, SEN 10%) | Belgium (MYS), Czech Republic, Ireland, Poland, Sweden, Switzerland, United Kingdom (MYS 0%–7%, SEN 0%–9%) | France, South Africa (SEN 2%–6%) | Australia, Japan (MYS 0%, SEN 0%–2%) |
| >10% | Argentina (SEN), Brazil (MYS), Chile, Colombia, Mexico, Venezuela (MYS 14%–17%, SEN 12%–26%) | Belgium (SEN), Germany (MYS 18%, SEN 14%–26%) | Greece, Israel, Italy, Spain, Turkey (MYS 14%–39%, SEN 14%–30%) | Hong Kong, Philippines, Singapore, Taiwan (SEN 12%–31%) | |
*For countries with <30 isolates in 2001, data from 2000 and 2001 were combined. Ranges of nonsusceptibility rates are indicated in parentheses. For ampicillin and trimethoprim/sulfamethoxazole, data are only available from the SENTRY system. MYS, MYSTIC; SEN, SENTRY.
Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.